For the roughly 1-in-20 adults living with schizophrenia, bipolar disorder, or severe major depression, a cancer diagnosis arrives with a set of compounding disadvantages that most oncology systems were not built to address. This matters because the same decades of progress that have extended survival for many cancer patients have largely bypassed this population — not because of biology alone, but because of structural and attitudinal failures in care delivery.
This review, published in CA: A Cancer Journal for Clinicians, synthesizes evidence showing that individuals with serious mental illness (SMI) already face a 20-to-30-year reduction in life expectancy before cancer enters the picture. Cancer then worsens that gap through several overlapping mechanisms: fragmented care pathways that separate psychiatric and oncologic services, reduced access to newer cancer therapeutics, underrepresentation in clinical trials that would generate evidence specific to this population, and a phenomenon termed diagnostic overshadowing — where new physical symptoms are incorrectly attributed to psychiatric illness, delaying cancer detection. Stigma among clinicians is identified as both a discrete barrier and an amplifier of the others. The review proposes a collaborative care model integrating psychosocial and psychiatric support directly into oncology settings, alongside bias-awareness reforms in clinical training.
This review lands in a journal whose readership comprises practicing oncologists, giving its recommendations unusual reach. Diagnostic overshadowing is a well-documented but underappreciated hazard — it has been flagged in neurological and cardiovascular contexts too, but cancer, where early detection is often survival-determinative, raises the stakes considerably. The collaborative care model proposed here has reasonable evidence behind it in depression-primary care settings, but its translation to oncology-psychiatry integration remains underexplored in prospective trials. The absence of SMI-specific cancer trial data creates a circular evidence gap: exclusion from trials means no data, which means no tailored protocols, which perpetuates exclusion. This review is more advocacy document than primary research, but its clinical audience and journal prominence make it potentially catalytic for practice change.